Halopemide, a new psychotropic agent. Cerebral distribution and receptor interactions.
A J Loonen, W Soudijn
Index: Pharm. Weekbl. Sci. 7(1) , 1-9, (1985)
Full Text: HTML
Abstract
Halopemide is a new psychotropic agent, a structural analogue of the neuroleptics of the butyrophenone type but with different pharmacological and clinical properties. Preliminary clinical findings indicate that halopemide lacks the ability to induce parkinsonism and may be an effective drug in the treatment of psychosis characterized by autism, emotional withdrawal or apathy. Its pharmacological effects at a molecular level in comparison to structurally related neuroleptics and putative metabolites are reviewed.
Related Compounds
Related Articles:
CAY10593 inhibits the human P2X7 receptor independently of phospholipase D1 stimulation.
2013-12-01
[Purinergic Signal. 9(4) , 609-19, (2013)]
[J. Chromatogr. A. 164(2) , 177-85, (1979)]
Endocrine effects of domperidone: a peripheral dopamine blocking agent.
1981-09-01
[Clin. Endocrinol. (Oxf.) 15(3) , 275-82, (1981)]
1980-09-01
[Arch. Int. Pharmacodyn. Ther. 247(1) , 43-58, (1980)]
1986-01-01
[Psychopharmacology 89(1) , 108-12, (1986)]